Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CEMI

Chembio Diagnostics (CEMI) Stock Price, News & Analysis

Chembio Diagnostics logo

About Chembio Diagnostics Stock (NASDAQ:CEMI)

Key Stats

Today's Range
$0.45
$0.46
50-Day Range
$0.33
$0.46
52-Week Range
$0.19
$1.24
Volume
351,642 shs
Average Volume
661,416 shs
Market Capitalization
$16.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CEMI Stock News Headlines

ANY LAB TEST NOW Forms Strategic Partnership with Chembio
Reagan’s former tech advisor sharing bombshell announcement
George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.tc pixel
Quest Diagnostics Inc DGX
See More Headlines

CEMI Stock Analysis - Frequently Asked Questions

Chembio Diagnostics, Inc. (NASDAQ:CEMI) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.05. The business had revenue of $12.06 million for the quarter. Chembio Diagnostics had a negative trailing twelve-month return on equity of 113.57% and a negative net margin of 47.03%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet (CLMT), Two Harbors Investments (TWO), NovoCure (NVCR), BlackRock Capital Investment (BKCC), Viper Energy (VNOM) and Summit Midstream Partners (SMLP).

Company Calendar

Last Earnings
11/04/2021
Today
9/16/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CEMI
CIK
1092662
Employees
337
Year Founded
1986

Profitability

EPS (Trailing Twelve Months)
($1.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$23.29 million
Net Margins
-47.03%
Pretax Margin
-46.96%
Return on Equity
-113.57%
Return on Assets
-38.22%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.23
Quick Ratio
1.04

Sales & Book Value

Annual Sales
$48.34 million
Price / Sales
0.35
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.48 per share
Price / Book
0.95

Miscellaneous

Outstanding Shares
36,726,000
Free Float
35,514,000
Market Cap
$16.71 million
Optionable
Not Optionable
Beta
1.85

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:CEMI) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners